Loading...
•
Dec 31, 2021
AbCellera Q4 2019 Earnings Report
AbCellera reported financial results for Q4 2021
Key Takeaways
AbCellera's Q4 2021 revenue reached $139.3 million, with royalties on bamlanivimab sales contributing $134.5 million and research fees accounting for $4.7 million. Net earnings for the quarter were $59.9 million, or $0.21 per share on a basic and $0.19 per share on a diluted basis.
Q4 2021 revenue was $139.3 million, representing 37% of the total for 2021.
Royalties on net sales of bamlanivimab generated $134.5 million in Q4 2021.
Research fees contributed $4.7 million in Q4 2021.
Net earnings for Q4 2021 were $59.9 million, or $0.21 per share on a basic and $0.19 per share on a diluted basis.
Revenue by Segment
Forward Guidance
AbCellera moves into 2022 with momentum and a strong cash position to continue to grow our business and to make investments that will increase the speed, efficiency, and scalability of our platform.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...